Tags

Type your tag names separated by a space and hit enter

Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Clin Exp Pharmacol Physiol. 2009 Mar; 36(3):287-96.CE

Abstract

1. Advanced glycation end-products (AGE) and their receptors (RAGE) have been implicated in renal damage in diabetes. The aim of the present study was to investigate the effects of benazepril, an angiotensin-converting enzyme inhibitor (ACEI), on the formation of AGE, the expression RAGE and other associated components in the oxidative stress pathway in spontaneously hypertensive rats (SHR). 2. Groups of SHR were treated with or without 10 mg/kg per day benazepril for 12 weeks. Systolic blood pressure (SBP) and angiotensin (Ang) II levels were evaluated in SHR and control Wistar-Kyoto (WKY) rats. Renal function was investigated by determining levels of proteinuria and glomerulosclerosis. Furthermore, reactive oxygen species (ROS) in the rat renal cortex were analysed using an H(2)O(2)-based hydroxyl radical-detection assay and the renal content of AGE, RAGE, NADPH oxidase p47phox, nuclear factor (NF)-kappaB p65, phosphorylated (p-) NF-kappaB p65, vascular cell adhesion molecule (VCAM)-1 and transforming growth factor (TGF)-beta1 was determined by immunohistochemistry, quantitative real-time polymerase chain reaction and western blot analysis. 3. Treatment with benazepril inhibited the formation of AngII, reduced SBP and alleviated renal lesions in SHR compared with both untreated SHR and control WKY rats. Benazepril treatment significantly suppressed the accumulation of AGE and expression of RAGE in the kidney of SHR. In addition, benazepril treatment reduced the upregulation of NADPH oxidase p47phox, ROS generation and NF-kappaB p65, p-NF-kappaB p65, VCAM-1 and TGF-beta1 expression in the kidney of SHR compared with both untreated SHR and control WKY rats. 4. The results of the present study provide new insights into the regulation by the renin-angiotensin system of AGE-RAGE, oxidative stress and nephropathy, increasing our understanding of the role of the RAS in nephropathy.

Authors+Show Affiliations

Department of Geriatrics, Shandong Provincial Hospital of Shandong University, Jinan, China. lxp6133@yahoo.com.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19018797

Citation

Liu, Xue-Ping, et al. "Benazepril, an Angiotensin-converting Enzyme Inhibitor, Alleviates Renal Injury in Spontaneously Hypertensive Rats By Inhibiting Advanced Glycation End-product-mediated Pathways." Clinical and Experimental Pharmacology & Physiology, vol. 36, no. 3, 2009, pp. 287-96.
Liu XP, Pang YJ, Zhu WW, et al. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol. 2009;36(3):287-96.
Liu, X. P., Pang, Y. J., Zhu, W. W., Zhao, T. T., Zheng, M., Wang, Y. B., Sun, Z. J., & Sun, S. J. (2009). Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clinical and Experimental Pharmacology & Physiology, 36(3), 287-96. https://doi.org/10.1111/j.1440-1681.2008.05078.x
Liu XP, et al. Benazepril, an Angiotensin-converting Enzyme Inhibitor, Alleviates Renal Injury in Spontaneously Hypertensive Rats By Inhibiting Advanced Glycation End-product-mediated Pathways. Clin Exp Pharmacol Physiol. 2009;36(3):287-96. PubMed PMID: 19018797.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. AU - Liu,Xue-Ping, AU - Pang,Yue-Jiu, AU - Zhu,Wei-Wei, AU - Zhao,Ting-Ting, AU - Zheng,Min, AU - Wang,Yi-Bing, AU - Sun,Zhi-Jian, AU - Sun,Siao-Jing, Y1 - 2008/11/10/ PY - 2008/11/21/pubmed PY - 2009/5/29/medline PY - 2008/11/21/entrez SP - 287 EP - 96 JF - Clinical and experimental pharmacology & physiology JO - Clin Exp Pharmacol Physiol VL - 36 IS - 3 N2 - 1. Advanced glycation end-products (AGE) and their receptors (RAGE) have been implicated in renal damage in diabetes. The aim of the present study was to investigate the effects of benazepril, an angiotensin-converting enzyme inhibitor (ACEI), on the formation of AGE, the expression RAGE and other associated components in the oxidative stress pathway in spontaneously hypertensive rats (SHR). 2. Groups of SHR were treated with or without 10 mg/kg per day benazepril for 12 weeks. Systolic blood pressure (SBP) and angiotensin (Ang) II levels were evaluated in SHR and control Wistar-Kyoto (WKY) rats. Renal function was investigated by determining levels of proteinuria and glomerulosclerosis. Furthermore, reactive oxygen species (ROS) in the rat renal cortex were analysed using an H(2)O(2)-based hydroxyl radical-detection assay and the renal content of AGE, RAGE, NADPH oxidase p47phox, nuclear factor (NF)-kappaB p65, phosphorylated (p-) NF-kappaB p65, vascular cell adhesion molecule (VCAM)-1 and transforming growth factor (TGF)-beta1 was determined by immunohistochemistry, quantitative real-time polymerase chain reaction and western blot analysis. 3. Treatment with benazepril inhibited the formation of AngII, reduced SBP and alleviated renal lesions in SHR compared with both untreated SHR and control WKY rats. Benazepril treatment significantly suppressed the accumulation of AGE and expression of RAGE in the kidney of SHR. In addition, benazepril treatment reduced the upregulation of NADPH oxidase p47phox, ROS generation and NF-kappaB p65, p-NF-kappaB p65, VCAM-1 and TGF-beta1 expression in the kidney of SHR compared with both untreated SHR and control WKY rats. 4. The results of the present study provide new insights into the regulation by the renin-angiotensin system of AGE-RAGE, oxidative stress and nephropathy, increasing our understanding of the role of the RAS in nephropathy. SN - 1440-1681 UR - https://www.unboundmedicine.com/medline/citation/19018797/Benazepril_an_angiotensin_converting_enzyme_inhibitor_alleviates_renal_injury_in_spontaneously_hypertensive_rats_by_inhibiting_advanced_glycation_end_product_mediated_pathways_ L2 - https://doi.org/10.1111/j.1440-1681.2008.05078.x DB - PRIME DP - Unbound Medicine ER -